WO2001056561A1 - Preventives for viral infection - Google Patents
Preventives for viral infection Download PDFInfo
- Publication number
- WO2001056561A1 WO2001056561A1 PCT/JP2001/000569 JP0100569W WO0156561A1 WO 2001056561 A1 WO2001056561 A1 WO 2001056561A1 JP 0100569 W JP0100569 W JP 0100569W WO 0156561 A1 WO0156561 A1 WO 0156561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cystine
- virus
- infection
- viral infection
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the present invention relates to a prophylactic agent or a method for preventing viral infection.
- AIDS caused by hepatitis and HIV.
- respiratory infectious viruses such as Innoleenzae innores, Rhinowinores, Coronawinores, Parainfluenza virus, RS virus, Adenovirus, and Leovirus are found in epithelial cells of the nasal cavity, pharynx, trachea, bronchi, and lungs. It is a virus that causes the disease that is commonly seen in daily life and proliferates and presents cold symptoms. The disease often recovers with mild symptoms such as rhinitis and pharyngitis, but may be accompanied by serious complications such as pneumonia, which may lead to death.
- symptomatic treatment including antipyretic analgesics such as acetaminophen, drugs for suppressing allergic symptoms such as chlorpheniramine maleate, and cold medicines containing antitussives such as methylefedrine hydrochloride. It is often taken as a non-prescription drug.
- doctors take antimicrobial drugs and take vitamins to cope with the concurrent occurrence of the above common cold medicine and secondary bacterial infection at hospitals. .
- influenza virus has many strains due to differences in its surface antigens, and is liable to cause antigenic variation.Therefore, it is important to match the antigen structure between vaccine strains and epidemic strains. Effectiveness cannot be demonstrated if different strains become prevalent. Also, as described above, many types of respiratory infectious viruses are known, and since there are many subtypes for each virus, there is a possibility that the virus type will be out of place with selective prevention methods. Where the epidemic virus type (subtype) does not hit In some cases.
- Mouthwash with an iodine preparation has been used as a method of preventing respiratory tract virus infection, but has the disadvantage of having a characteristic bitter taste.
- Amantadine or rimantadine which has an anti-influenza virus A activity, is used in the United States for the purpose of preventing infection (MMWR, 44, RR-3, 1995), but the risk of emergence of resistant strains or side effects There are many restrictions in terms of general dissemination such as the possibility of appearance. Thus, at present, there are not enough preventive measures against respiratory tract virus infections, leaving problems to be solved.
- the present invention provides an active ingredient for preventing viral infections for which there is no satisfactory preventive measure, and in particular, provides an active ingredient for respiratory tract infections by preventing the disease by taking it at the time of the epidemic. Is to do.
- the present inventors have conducted intensive studies to solve the problems described in the preceding paragraph, and as a result, have found that cystine has a preventive effect against viral infections, and have completed the present invention. That is, the invention according to the present application is a method for preventing a viral infectious disease, comprising administering cystine as an active ingredient, and comprising administering a prophylactic agent for a viral infectious disease and administering cystine to a human or animal. .
- Virus infections to which the prophylactic agent of the present invention can be applied include shingles caused by herpes virus, diarrhea caused by rotavirus, viral hepatitis, AIDS, and the like. It is effective for Organisms targeted by respiratory infectious viruses include turkeys, chickens, etc., in addition to humans This can be applied to domestic poultry, domestic animals such as pigs, and animals such as pets such as cats and dogs. Among them, the use of economic animals, such as poultry and livestock, not only reduces the economic loss of livestock, but also uses them for food, thus preventing infection of humans. It is also an important application.
- the dose of the active ingredient cystine ranges from 200 / ig / kg to 300 mg / kg per day, preferably 500 g / kg to 100 mg / kg per day. It may be administered in several or divided doses.
- the administration period is not particularly limited.
- the active ingredient cystine may be administered, for example, in the form of tablets, granules, powders, capsules, elixirs, microcapsules or suspensions, powdered beverages such as powdered milk, foods such as beverages and confectionery Can also be administered.
- it can be administered orally in addition to feed. It can be administered orally before or after a meal, or a cystine-containing solution can be sprayed intranasally.
- the cystine used as the active ingredient of the present invention is preferably L-cystine, and can be administered as a physiologically acceptable salt compound or mixture. In addition, it can be administered together with carriers, excipients, binders, preservatives, stabilizers and the like in the unit dosage form generally required for the practice of pharmaceutical preparations.
- the amount of active substance in these compositions or preparations should be such that a suitable dosage in the range indicated is obtained.
- Binders such as tragacanth, gum arabic, corn starch or gelatin, excipients such as microcrystalline cellulose, corn starch, pregelatinized starch, leavening agents such as alginic acid, lubrication such as magnesium stearate.
- sweetening agents such as sucrose, lactose or aspartame, flavoring agents such as peppermint, cocoa oil or cherry can be used.
- the preparation unit form is capsule, the above type of material may further contain a liquid carrier such as oil and fat. In the case of tablets, they can be coated with shellac, sugar or both.
- sucrose as a sweetening agent
- methyl and propylparabens as preservatives
- dyes and cellulose or orene Di flavor can be included.
- various vitamins and various amino acids may be contained in a preparation containing cystine as an active ingredient.
- an enteric formulation for example, an aqueous solution of hydroxyphenylphenylmethylcellulose is used as a pretreatment agent for coating, or an aqueous solution of hydroxypropylmethylcellulose phthalate and an aqueous solution of polyacetin are used as coating agents. It may be a formulation.
- FIG. 1 is a diagram showing the amount of influenza virus in the lungs of mice on day 5 of infection in the example
- FIG. 2 is a diagram showing the rate of weight change of mice 5 days after infection in the example. is there.
- 6-week-old BALB / c female mice in the growing season are reared on a diet containing 20% casein (basic diet) as a protein source for 1 week, and then fed with 0.5% L-cystine in the same diet. They were reared for another 2 weeks. In addition, those that were continuously bred with the basic diet were used as a control group. Ten animals were used for the test in each group. Then 1 0 5 PFU inflation Ruenzawirusu A / Aichi / 2/68 and (H3N2) was nasally inoculated. On day 5 after virus inoculation, the lungs of mice were excised, and the amount of the virus was determined as the infectious titer of black formation using MDCK cells (derived from dog kidney).
- MDCK cells derived from dog kidney
- ADVANTAGE OF THE INVENTION Virus infection can be suppressed and the weight loss accompanying infection can be reduced by the prophylactic agent and prophylactic method of viral infection of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
明 細 書 Specification
ウィルス感染症予防剤 技術分野 Virus Infectious Disease Prevention Agent Technical Field
本発明は、 ウィルス感染症の予防剤または予防方法に関する。 背景技術 The present invention relates to a prophylactic agent or a method for preventing viral infection. Background art
ウィルス感染症は肝炎や HIVを原因とする AIDSなどをはじめとし、多数知ら れている。 そのうち、 イ ンフノレエンザゥイノレス、 ライノウイノレス、 コロナウイノレ ス、 パラインフルエンザウイルス、 RS ウィルス、 アデノ ウイルス、 レオウィル スなどの呼吸器感染性ウィルスは鼻腔から咽頭、 気管、 気管支、 肺の上皮系細胞 で増殖し、 かぜ症状を呈する日常で多くみられる疾患の原因ウィルスである。 多 くは軽い鼻炎や咽頭炎などの症状で回復するが、 肺炎などの重篤な合併症を併発 し死の帰転に至る場合もあり、 注意を要する疾患である。 ス ト レスなどによって 免疫力が低下し生体側が感染を防御しきれなくなった時、 症状として現われる。 現状における治療方法は対症療法が一般的で、 ァセトアミノフェン等の解熱鎮痛 薬、 マレイン酸クロルフエ二ラミン等アレルギー症状を抑える薬剤、 塩酸メチル ェフエドリン等の鎮咳薬等が配合された感冒薬などを非処方箋薬として服用する 場合が多い。 また、 症状が比較的重くなりだした際、 病院にて医師から上記感冒 薬や細菌の二次感染の併発に対処した抗菌剤の服用ゃビタミン剤の摂取が行われ ているのが現状である。 Many viral infections are known, including AIDS caused by hepatitis and HIV. Of these, respiratory infectious viruses such as Innoleenzae innores, Rhinowinores, Coronawinores, Parainfluenza virus, RS virus, Adenovirus, and Leovirus are found in epithelial cells of the nasal cavity, pharynx, trachea, bronchi, and lungs. It is a virus that causes the disease that is commonly seen in daily life and proliferates and presents cold symptoms. The disease often recovers with mild symptoms such as rhinitis and pharyngitis, but may be accompanied by serious complications such as pneumonia, which may lead to death. It manifests as a symptom when the immunity is reduced due to stress or the like and the living body cannot protect the infection. At present, symptomatic treatment is generally used, including antipyretic analgesics such as acetaminophen, drugs for suppressing allergic symptoms such as chlorpheniramine maleate, and cold medicines containing antitussives such as methylefedrine hydrochloride. It is often taken as a non-prescription drug. In addition, when symptoms become relatively severe, doctors take antimicrobial drugs and take vitamins to cope with the concurrent occurrence of the above common cold medicine and secondary bacterial infection at hospitals. .
一方、 予防的な処方としてはこれら原因ウィルスのうち最も重要なインフルェ ンザに対する不活化ワクチンの予防接種が流行期前に用いられる。 ィンフルェン ザウィルスはその表面抗原の違いにより多くの株が存在し、 しかも抗原変異を起 こし易いことから、ワクチン株と流行株との抗原構造の一致が重要な問題となり、 予測により接種したワクチンと異なった株が流行した場合には有効性が発揮でき ない。 また、 呼吸器感染性ウィルスは前述のように多くの種類が知られており、 しかもそれぞれのウィルスごとに多くの亜型が存在する為、 ウィルスのタイプに 選択的な予防法ではあたり外れがあり流行のウィルス型 （亜型） が的中しない場 合もある。 On the other hand, as a preventive prescription, vaccination with an inactivated vaccine against influenza, the most important of these causative viruses, is used before the epidemic. Influenza virus has many strains due to differences in its surface antigens, and is liable to cause antigenic variation.Therefore, it is important to match the antigen structure between vaccine strains and epidemic strains. Effectiveness cannot be demonstrated if different strains become prevalent. Also, as described above, many types of respiratory infectious viruses are known, and since there are many subtypes for each virus, there is a possibility that the virus type will be out of place with selective prevention methods. Where the epidemic virus type (subtype) does not hit In some cases.
また、 呼吸器感染性ウィルス感染症の予防法としてョゥ素製剤によるうがい液 が用いられているが、 特有の苦味を有するという欠点がある。 また、 抗インフル ェンザウィルス A型作用を有するァマンタジンあるいはリマンタジンが米国で感 染予防の目的で用いられているが （MMWR,44，RR-3，1995)、 耐性株出現の危険性 の問題、あるいは副作用出現の可能性など一般的な普及という点では制約も多い。 このように現状では呼吸器感染性ウィルス感染症に対する予防法は必ずしも十 分で無く、 解決すべき問題点を残している。 一方、 PCT/US98/00380においてグル タチオン、 ダルタチオンジスルフィ ド、 ァスコルビン酸、 N—ァセチルシスティ ンが細胞培養による感染抑制効果を有することが報告されているが、 その in vivo における効果は不明である。 また、 ビタミン Eの老齢マウスにおけるインフルェ ンザウィルスの感染抑制効果が報告されているが、 6週間以上の極めて長期摂取 が必要である。 また、 セレノシスチンがマウスにおいてインフルエンザウイルス 感染抑制効果を有することが報告されている （Ho et al、 Antimicrobial Agents and Chemotherapy, 1967年）。 発明の開示 Mouthwash with an iodine preparation has been used as a method of preventing respiratory tract virus infection, but has the disadvantage of having a characteristic bitter taste. Amantadine or rimantadine, which has an anti-influenza virus A activity, is used in the United States for the purpose of preventing infection (MMWR, 44, RR-3, 1995), but the risk of emergence of resistant strains or side effects There are many restrictions in terms of general dissemination such as the possibility of appearance. Thus, at present, there are not enough preventive measures against respiratory tract virus infections, leaving problems to be solved. On the other hand, PCT / US98 / 00380 reports that glutathione, daltathione disulfide, ascorbic acid, and N-acetylcystin have an infection-suppressing effect by cell culture, but their in vivo effects are unknown. . In addition, it has been reported that vitamin E suppresses infection of influenza virus in aged mice, but requires an extremely long-term intake of 6 weeks or more. It has also been reported that selenocystin has an inhibitory effect on influenza virus infection in mice (Ho et al, Antimicrobial Agents and Chemotherapy, 1967). Disclosure of the invention
本発明は満足な予防手段の無いウィルス感染症に対し予防する有効成分を提供 すること、 特に呼吸器感染ウィルス感染症に対し、 流行の時期に服用することに より罹患を予防する有効成分を提供することにある。 The present invention provides an active ingredient for preventing viral infections for which there is no satisfactory preventive measure, and in particular, provides an active ingredient for respiratory tract infections by preventing the disease by taking it at the time of the epidemic. Is to do.
本発明者は、 前項記載の課題を解決すべく鋭意研究を行った結果、 シスチンが ウィルス感染症に対し予防効果を有することを見出し本発明を完成するに至った。 即ち、 本出願に係る発明は、 シスチンを有効成分として含有することを特徴と するでウィルスの感染症の予防剤およびシスチンを人または動物に投与すること からなる、 ウィルス感染症の予防方法である。 The present inventors have conducted intensive studies to solve the problems described in the preceding paragraph, and as a result, have found that cystine has a preventive effect against viral infections, and have completed the present invention. That is, the invention according to the present application is a method for preventing a viral infectious disease, comprising administering cystine as an active ingredient, and comprising administering a prophylactic agent for a viral infectious disease and administering cystine to a human or animal. .
本発明の予防剤が適応できるウィルス感染症として、 ヘルぺスウィルスを原因 とする帯状疱疹、 ロタウィルスを原因とする下痢、 ウィルス性肝炎、 AIDS、 など が挙げられるが、 特に呼吸器感染性ウィルスに対して効果的である。 呼吸器感染 性ウィルスの標的となる生物として、 ヒ ト以外にシチメンチョウ、 ニヮ トリなど の家禽類、 ブタゃゥマなどの家畜類、 猫や犬などのペッ ト類等の動物に適用でき る。 なかでお、 家禽類、 家畜類に代表される経済動物への利用は、 家畜の経済的 損失を軽減するのみならず、 それらを食用とする場合も多いため、 ヒ 卜への感染 予防という点からも重要な用途になる。 Virus infections to which the prophylactic agent of the present invention can be applied include shingles caused by herpes virus, diarrhea caused by rotavirus, viral hepatitis, AIDS, and the like. It is effective for Organisms targeted by respiratory infectious viruses include turkeys, chickens, etc., in addition to humans This can be applied to domestic poultry, domestic animals such as pigs, and animals such as pets such as cats and dogs. Among them, the use of economic animals, such as poultry and livestock, not only reduces the economic loss of livestock, but also uses them for food, thus preventing infection of humans. It is also an important application.
有効成分であるシスチンの投与量は、 1 日あたり 2 0 0 /i g / k g ~ 3 0 0 m g / k g好ましくは 5 0 0 g / k g ~ l 0 0 m g / k gの範囲であり、 1 日 1回もしく は数回に分けて投与すればよい。 また、 投与期間は特に問わない。 The dose of the active ingredient cystine ranges from 200 / ig / kg to 300 mg / kg per day, preferably 500 g / kg to 100 mg / kg per day. It may be administered in several or divided doses. The administration period is not particularly limited.
有効成分であるシスチンは、 例えば錠剤、 顆粒剤、 散剤、 カプセル剤、 エリキ シル剤、 マイクロカプセル剤あるいは懸濁液剤の形で投与してもよく、 粉ミルク などの粉末飲料や飲料、 菓子などの食品の中に添加して投与することもできる。 また、 家禽類や家畜においては、 飼料に添加して経口で投与することができる。 食前あるいは食後経口的に投与することもできる他、 シスチンを含有溶液を点鼻 噴霧することもできる。 The active ingredient cystine may be administered, for example, in the form of tablets, granules, powders, capsules, elixirs, microcapsules or suspensions, powdered beverages such as powdered milk, foods such as beverages and confectionery Can also be administered. In poultry and livestock, it can be administered orally in addition to feed. It can be administered orally before or after a meal, or a cystine-containing solution can be sprayed intranasally.
本発明の有効成分として使用するシスチンは、 L—シスチンが好ましく、 生理 学的に認められる塩の化合物または混合物として投与することができる。 また、 担体、 賦形剤、 結合剤、 防腐剤、 安定剤などとともに一般に認められた製剤実施 に要求される単位用量形態で投与することができる。 これらの組成物または製剤 における活性物質の量は指示された範囲の適当な用量が得られるようにすればよ レ、。 The cystine used as the active ingredient of the present invention is preferably L-cystine, and can be administered as a physiologically acceptable salt compound or mixture. In addition, it can be administered together with carriers, excipients, binders, preservatives, stabilizers and the like in the unit dosage form generally required for the practice of pharmaceutical preparations. The amount of active substance in these compositions or preparations should be such that a suitable dosage in the range indicated is obtained.
錠剤、 カプセル剤などに混和することができる具体的な成分の例は次に示すも のである。 すなわち、 トラガント、 アラビアゴム、 コーンスターチまたはゼラチ ンのような結合剤、 微晶性セルロースのような賦形剤、 コーンスターチ、 前ゼラ チン化デンプン、 アルギン酸のような膨化剤、 ステアリン酸マグネシウムのよう な潤滑剤、 ショ糖、 乳糖またはアスパルテームのような甘味剤、 ペパーミント、 ァカモノ油またはチェリーのような香味剤が使用可能である。 調剤単位形態が力 プセルである場合には、 上記のタイプの材料にさらに油脂のような液状担体を含 有することができる。 尚、 錠剤の場合はシヱラック、 砂糖またはその両方で被服 することができる。 シロップまたはエリキシルの場合は、 甘味剤としてショ糖、 防腐剤としてメチルおよびプロピルパラベン、 色素およびチェリ一またはオレン ジ香味を含有することができる。 その他、 各種ビタミン類、 各種アミノ酸類をシ スチンを有効成分とする製剤に含有しても良い。 Examples of specific components that can be mixed with tablets, capsules, etc. are shown below. Binders such as tragacanth, gum arabic, corn starch or gelatin, excipients such as microcrystalline cellulose, corn starch, pregelatinized starch, leavening agents such as alginic acid, lubrication such as magnesium stearate. Sweetening agents such as sucrose, lactose or aspartame, flavoring agents such as peppermint, cocoa oil or cherry can be used. When the preparation unit form is capsule, the above type of material may further contain a liquid carrier such as oil and fat. In the case of tablets, they can be coated with shellac, sugar or both. In the case of syrups or elixirs, sucrose as a sweetening agent, methyl and propylparabens as preservatives, dyes and cellulose or orene Di flavor can be included. In addition, various vitamins and various amino acids may be contained in a preparation containing cystine as an active ingredient.
腸溶製剤とするときは、 例えばヒ ドロキシルフェニルメチルセルロースの水溶 液を被服前処理剤とし、 またはヒ ドロキシプロピルメチルセルロースフタレート の水溶液およびポリアセチンの水溶液を被服剤とし、 それぞれ使用し常法により 腸溶製剤とすればよい。 図面の簡単な説明 When an enteric formulation is used, for example, an aqueous solution of hydroxyphenylphenylmethylcellulose is used as a pretreatment agent for coating, or an aqueous solution of hydroxypropylmethylcellulose phthalate and an aqueous solution of polyacetin are used as coating agents. It may be a formulation. BRIEF DESCRIPTION OF THE FIGURES
図 1は、 実施例における、 感染 5 日目のマウスの肺のインフルエンザウイルス 量を示す図であり、 図 2は、 実施例における、 感染後 5 日間でのマウスの体重変 化率を示す図である。 発明を実施するための最良の形態 FIG. 1 is a diagram showing the amount of influenza virus in the lungs of mice on day 5 of infection in the example, and FIG. 2 is a diagram showing the rate of weight change of mice 5 days after infection in the example. is there. BEST MODE FOR CARRYING OUT THE INVENTION
以下、 実施例を挙げて本発明を具体的に説明し、 その有効性を示す。 Hereinafter, the present invention will be described specifically with reference to examples, and its effectiveness will be described.
<実施例 > <Example>
成長期にある 6週齢の BALB/c雌性マウスをタンパク質源としてカゼィンを 2 0 %含む飼料 （基本食） で 1週間飼育後、 同飼料に L—シスチンを 0 . 5 %添カロ した飼料に切り換え更に 2週間飼育した。 また基本食のまま継続して飼育したも のを対照群とした。 各群とも 1 0匹を試験に用いた。 次いで 1 0 5 PFUのインフ ルェンザウィルス A/Aichi/2/68(H3N2)を経鼻接種した。 ウィルス接種 5 日目に、 マウスの肺を摘出し、 そのウィルス量を MDCK細胞 （ィヌの腎臓由来） を用い たブラック形成による感染価として求めた。 また感染前後の体重を測定した。 その結果を図 1、 図 2に示す。 L一シスチンを添加しない基本食飼料摂取群を 対照としたところ、 肺のウィルス量は 6 . 1 1 ± 0 . 2 1 log10PFU/g であった のに対し、 L一シスチン添加群では 5 . 7 2 ± 0 . 2 5 1og10PFU/g であり、 有 意に （P < 0 . 0 5 ) 感染抑制効果を示した。 一方、 対照群が感染により 5日間 で 0 . 9 0 %の体重減少を示したのに対し、 L一シスチン添加群では逆に 3 . 4 8 %の体重増加を示した。 従って、 0 . 5 % L—シスチン添加群はインフルェン ザウィルス感染によって惹起される体重減少障害を克服していることが示された。 産業上の利用可能性 6-week-old BALB / c female mice in the growing season are reared on a diet containing 20% casein (basic diet) as a protein source for 1 week, and then fed with 0.5% L-cystine in the same diet. They were reared for another 2 weeks. In addition, those that were continuously bred with the basic diet were used as a control group. Ten animals were used for the test in each group. Then 1 0 5 PFU inflation Ruenzawirusu A / Aichi / 2/68 and (H3N2) was nasally inoculated. On day 5 after virus inoculation, the lungs of mice were excised, and the amount of the virus was determined as the infectious titer of black formation using MDCK cells (derived from dog kidney). The body weight before and after the infection was measured. Figures 1 and 2 show the results. When the control group was the basal diet without L-cystine, the lung viral load was 6.11 ± 0.21 log 10 PFU / g, whereas the L-cystine group did not. It was 0.72 ± 0.25 1 og 10 PFU / g, and significantly (P <0.05) showed an infection-suppressing effect. On the other hand, the control group showed 0.90% weight loss in 5 days due to infection, whereas the L-cystine-added group showed 3.48% weight gain. Therefore, it was shown that the group supplemented with 0.5% L-cystine overcomes the weight loss disorder caused by influenza virus infection. Industrial applicability
本発明のウィルス感染症予防剤および予防方法により、 ウィルス感染を抑制す ることができ、 感染に伴う体重減少を軽減できる。 ADVANTAGE OF THE INVENTION Virus infection can be suppressed and the weight loss accompanying infection can be reduced by the prophylactic agent and prophylactic method of viral infection of the present invention.
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-025148 | 2000-02-02 | ||
| JP2000025148A JP3988014B2 (en) | 2000-02-02 | 2000-02-02 | Antiviral agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001056561A1 true WO2001056561A1 (en) | 2001-08-09 |
Family
ID=18551045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2001/000569 Ceased WO2001056561A1 (en) | 2000-02-02 | 2001-01-29 | Preventives for viral infection |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3988014B2 (en) |
| WO (1) | WO2001056561A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767714B2 (en) | 2002-02-18 | 2010-08-03 | Ajinomoto Co., Inc. | Method of preventing infectious diseases |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE340569T1 (en) * | 2002-02-18 | 2006-10-15 | Ajinomoto Kk | USE OF A NEW AGENT TO PREVENT INFECTIONS |
| JP6814312B1 (en) * | 2020-02-05 | 2021-01-13 | 株式会社タイショーテクノス | How to impart antiviral properties to antiviral agents and articles |
| US20240139277A1 (en) * | 2020-05-20 | 2024-05-02 | Tohoku University | Drug containing active sulfur compound as its main component |
| CN119157868B (en) * | 2024-09-14 | 2025-05-16 | 中国科学院水生生物研究所 | Application of fumaric acid in preventing and treating grass carp reovirus infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018594A1 (en) * | 1990-06-08 | 1991-12-12 | Aktiebolaget Astra | The pharmacological use of certain cystine derivatives |
| WO1997046229A1 (en) * | 1996-06-06 | 1997-12-11 | Astra Aktiebolag | New use of derivatives of cystine |
| US6013632A (en) * | 1997-01-13 | 2000-01-11 | Emory University | Compounds and their combinations for the treatment of influenza infection |
-
2000
- 2000-02-02 JP JP2000025148A patent/JP3988014B2/en not_active Expired - Lifetime
-
2001
- 2001-01-29 WO PCT/JP2001/000569 patent/WO2001056561A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018594A1 (en) * | 1990-06-08 | 1991-12-12 | Aktiebolaget Astra | The pharmacological use of certain cystine derivatives |
| WO1997046229A1 (en) * | 1996-06-06 | 1997-12-11 | Astra Aktiebolag | New use of derivatives of cystine |
| US6013632A (en) * | 1997-01-13 | 2000-01-11 | Emory University | Compounds and their combinations for the treatment of influenza infection |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767714B2 (en) | 2002-02-18 | 2010-08-03 | Ajinomoto Co., Inc. | Method of preventing infectious diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001213774A (en) | 2001-08-07 |
| JP3988014B2 (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5191955B2 (en) | Mucosal immunomodulator and use thereof | |
| CN103648491B (en) | Method and pharmaceutical composition for suppressing influenza virus duplication | |
| US12478656B2 (en) | Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals | |
| JPWO2005007640A1 (en) | Composition for preventing or treating viral infection | |
| CN101873861A (en) | Anti-viral infection composition containing poly-gamma-glutamic acid | |
| KR101388061B1 (en) | Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep | |
| US10881621B2 (en) | Sintered ferrous amino acid particles and use of the same against a virus | |
| US6995190B2 (en) | Method and treatment with ketoprofen solution | |
| US20090074893A1 (en) | Antiviral peptides | |
| KR101160743B1 (en) | Anti-viral agent against avian influenza virus comprising green tea | |
| WO2001056561A1 (en) | Preventives for viral infection | |
| JP2019214555A (en) | Composition for prevention of virus infection | |
| RU2237475C1 (en) | Combined preparation to remove symptoms of catarrhal diseases and grippe (variants) | |
| US20200138726A1 (en) | Sintered nanoparticles and use of the same against a virus | |
| US7767714B2 (en) | Method of preventing infectious diseases | |
| JP3953031B2 (en) | New preventive agent for infectious diseases | |
| US11717503B2 (en) | Application of valine in preparing medicine for treating or preventing avian influenza virus infection | |
| CN116847854A (en) | Antiviral composition containing fucosyllactose as an active ingredient | |
| CN102727502B (en) | Resisiting influenza virus compositions and diet product, feedstuff and pharmaceuticals | |
| RU1818095C (en) | Agent for prophylaxis and treatment of bronchopneumonia in agricultural animals | |
| WO2004105792A1 (en) | Composition against parvovirus infection | |
| KR20220087654A (en) | Antiviral composition containing Mori Ramulus derived compound as an active ingredient | |
| US20060147481A1 (en) | Ketoprofen powder for oral use | |
| JPH07188032A (en) | Influenza remedy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |